Teduglutide for Short Bowel Syndrome: 24 month predicted versus actual analysis, June 2022
Page last updated: 21 October 2022
Drug utilisation sub-committee (DUSC)
June 2022
Abstract
Purpose
To compare the predicted and actual utilisation of teduglutide for Type III Short Bowel Syndrome with intestinal failure in the first 24 months of PBS listing.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Teduglutide was listed on the PBS, for this indication, on 1 October 2019.
Data Source / methodology
Data extracted from the PBS, Authorities and Date of Death databases maintained by Department of Health and Aged Care, processed by Services Australia were used for analyses.
Key Findings
- There were 24 and 33 patients treated with teduglutide during the first and second year of its listing respectively, which was XXXX than estimated.
- There were 215 and 277 teduglutide prescriptions dispensed during the first and second year of its listing respectively, which was XXXX than estimated.
- The median age of patients initiating teduglutide treatment was 47 years old. There was a wider age distribution for males compared to females.
- The data were too immature to analyse the time of teduglutide treatment, the median treatment duration was not reached by 31 December 2021.
Full Report
